Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer
March 08 2023 - 9:00AM
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome
editing company, today announced the appointment of Linea Aspesi as
the Company’s Executive Vice President and Chief People Officer.
Ms. Aspesi will lead Editas’ human resources department and the
Company’s people strategy in support of its mission and goals.
“Our people and our culture are critical ingredients for the
success of our new strategy, and we are fortunate to have someone
of Linea’s caliber and expertise in defining, shaping, and
implementing talent strategies for accelerated company growth. I
look forward to working with Linea and the Leadership Team to help
drive our talented team towards our goal of becoming a
commercial-stage organization and transforming the lives of people
living with serious diseases,” said Gilmore O’Neill, M.B., M.M.Sc.,
President and Chief Executive Officer, Editas Medicine.
“People are truly the foundation to making any company
successful. With our new strategy, we have a unique opportunity to
reengage with and inspire our talented team to develop and grow
into the future. I am excited to partner with our Leadership Team
and our employees to make an impact in the lives of patients around
the world,” said Linea Aspesi, Executive Vice President and Chief
People Officer, Editas Medicine.
Ms. Aspesi brings to Editas more than 25 years experience,
including 15 years in the life sciences sector, aligning talent
plans to company vision, mission, values and partnering with senior
leaders to define and drive cultural transformation strategies.
Ms. Aspesi joins Editas from Forma Therapeutics, where she
served as Chief Human Resources Officer and successfully led the
negotiations related to the people elements of the US $1B
acquisition of Forma by Novo Nordisk in late 2022. Prior to joining
Forma, Ms. Aspesi served as Saniona’s first Chief Human Resources
Officer. She also served as Vice President and Head of Human
Resources and Office Management for North America at Sobi, Inc.
Earlier in her career, Ms. Aspesi held positions of increasing
responsibility at Sanofi and Genzyme, including her most recent
position as Head of Human Resources to the Industrial Affairs
organization in North America.
Ms. Aspesi earned a Bachelor of Arts in Education from the
University of Massachusetts, Amherst.
About Editas MedicineAs a
clinical-stage genome editing company, Editas Medicine is focused
on translating the power and potential of the CRISPR/Cas9 and
CRISPR/Cas12a genome editing systems into a robust pipeline of
treatments for people living with serious diseases around the
world. Editas Medicine aims to discover, develop, manufacture, and
commercialize transformative, durable, precision genomic medicines
for a broad class of diseases. Editas Medicine is the exclusive
licensee of Broad Institute and Harvard University’s Cas9 patent
estates and Broad Institute’s Cas12a patent estate for human
medicines. For the latest information and scientific presentations,
please visit www.editasmedicine.com.
Forward-Looking StatementsThis press release
contains forward-looking statements and information within the
meaning of The Private Securities Litigation Reform Act of 1995.
The words "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "plan," "potential," "predict,"
"project," "target," "should," "would," and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. The
Company may not actually achieve the plans, intentions, or
expectations disclosed in these forward-looking statements, and you
should not place undue reliance on these forward-looking
statements. Actual results or events could differ materially from
the plans, intentions and expectations disclosed in these
forward-looking statements as a result of various important
factors, including: uncertainties inherent in the initiation and
completion of preclinical studies and clinical trials, and clinical
development of the Company’s product candidates; availability and
timing of results from preclinical studies and clinical trials;
whether interim results from a clinical trial will be predictive of
the final results of the trial or the results of future trials;
expectations for regulatory approvals to conduct trials or to
market products and availability of funding sufficient for the
Company’s foreseeable and unforeseeable operating expenses and
capital expenditure requirements. These and other risks are
described in greater detail under the caption “Risk Factors”
included in the Company’s most recent Annual Report on Form 10-K,
which is on file with the Securities and Exchange Commission,
and in other filings that the Company may make with
the Securities and Exchange Commission in the future. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and the Company expressly disclaims any
obligation to update any forward-looking statements, whether
because of new information, future events or otherwise.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/0a8f135a-e273-4d1f-b8af-89d322609647
Editas Medicine Contacts:
Media
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
Investors
Ron Moldaver
(617) 401-9052
ir@editasmed.com
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Jul 2024 to Jul 2024
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Jul 2023 to Jul 2024